{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:38:00Z","timestamp":1787647080632,"version":"build-2736575974"},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,6,25]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Appropriate dosing of gentamicin in critically ill neonates is still debated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>To assess the peak concentration (Cmax) and area-under-the-time-concentration curve (AUC0-24) of gentamicin and to simulate the recommended doses using the Monte Carlo method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>This was a retrospective study on critically ill neonates carried over a one-year period. The demographic characteristics, dosage regimen and gentamicin concentrations were recorded for each neonate. Using Bayesian pharmacokinetic modeling, Cmax and AUC0-24 were predicted. Dose recommendations for the target Cmax (\u03bcg\/ml) of 12 were obtained, and Monte Carlo simulation (100,000 iterations) was used for predicting the pharmacokinetic parameters and recommended doses for various birth weight categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Eighty-two critically ill neonates (with an average gestational age of 33.7 weeks; and birth weight of 2.1 kg) were recruited. Higher Cmax and AUC0-24 values were predicted in premature neonates, with greater cumulative AUCs in extremely preterm neonates. The average administered dose was 4 mg\/kg\/day and 75% of the participants had Cmax greater than 12 \u03bcg\/ml following a single dose, and 85% were found to be at steady state. On the contrary, only 25% of the study population had the recommended AUC0-24 (above 125 \u03bcg-hr\/ml). Simulation tests indicate that 90% of the critically ill neonates would achieve recommended Cmax with doses ranging between 5 and 6 mg\/kg\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Currently used dose of 4 mg\/kg\/day is adequate to maintain Cmax in a large majority of the study population, with one-fourth population reporting the recommended AUC0-24. Increasing the dose to 5-6 mg\/kg\/day will more likely help to achieve both the recommended Cmax and AUC0-24 values.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200221666200512111131","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:28:03Z","timestamp":1589286483000},"page":"270-280","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dose Optimization of Gentamicin in Critically Ill Neonates"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":true,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Therapeutics, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Al Jufairi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Mohamed","family":"Qader","sequence":"additional","affiliation":[{"name":"College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola A.M.","family":"Elsegai","sequence":"additional","affiliation":[{"name":"Department of Pathology-Biochemistry, Salmaniya Medical Hospital, Ministry of Health, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/INF.0000000000000542","volume":"34","author":"Cantey J.B.","year":"2015","unstructured":"Cantey J.B.; Wozniak P.S.; S\u00e1nchez P.J.; Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study. Pediatr Infect Dis J 2015,34(3),267-272","journal-title":"Pediatr Infect Dis J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00007691-200208000-00011","volume":"24","author":"Stolk L.M.","year":"2002","unstructured":"Stolk L.M.; Degraeuwe P.L.; Nieman F.H.; de Wolf M.C.; de Boer A.; Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002,24(4),527-531","journal-title":"Ther Drug Monit"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2217\/fmb-2017-0058","volume":"12","author":"Rivera-Chaparro N.D.","year":"2017","unstructured":"Rivera-Chaparro N.D.; Cohen-Wolkowiez M.; Greenberg R.G.; Dosing antibiotics in neonates: review of the pharmacokinetic data. Future Microbiol 2017,12,1001-1016","journal-title":"Future Microbiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/jac\/48.6.887","volume":"48,","author":"Stickland M.D.","year":"2001,","unstructured":"Stickland M.D.; Kirkpatrick C.M.; Begg E.J.; Duffull S.B.; Oddie S.J.; Darlow B.A.; An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother, 2001,,48,,887-893.5..","journal-title":"J Antimicrob Chemother,"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e02004","DOI":"10.1128\/AAC.02004-17","volume":"62","author":"van Donge T.","year":"2018","unstructured":"van Donge T.; Pfister M.; Bielicki J.; Csajka C.; Rodieux F.; van den Anker J.; Fuchs A.; Quantitative analysis of gentamicin exposure in neonates and infants calls into question its current dosing recommendations. Antimicrob Agents Chemother 2018,62(4),e02004-e02017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12887-019-1676-3","volume":"19","author":"Bergenwall M.","year":"2019","unstructured":"Bergenwall M.; Walker S.A.N.; Elligsen M.; Iaboni D.C.; Findlater C.; Seto W.; Ng E.; Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation - a retrospective study. BMC Pediatr 2019,19(1),318","journal-title":"BMC Pediatr"},{"key":"ref=7","author":"Klein J.M.","unstructured":"Klein J.M.; Drug monitoring levels in the NICU","journal-title":"Drug monitoring levels in the NICU"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","volume":"62","author":"Neely M.N.","year":"2018","unstructured":"Neely M.N.; Kato L.; Youn G.; Kraler L.; Bayard D.; van Guilder M.; Schumitzky A.; Yamada W.; Jones B.; Minejima E.; Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother 2018,62(2),e02042-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/FTD.0000000000000432","volume":"39","author":"Hodiamont C.J.","year":"2017","unstructured":"Hodiamont C.J.; Janssen J.M.; de Jong M.D.; Math\u00f4t R.A.; Juffermans N.P.; van Hest R.M.; Therapeutic drug monitoring of gentamicin peak concentrations in critically ill patients. Ther Drug Monit 2017,39(5),522-530","journal-title":"Ther Drug Monit"},{"key":"ref=10","first-page":"1109","volume":"84","author":"Chotigeat U.","year":"2001","unstructured":"Chotigeat U.; Narongsanti A.; Ayudhya D.P.; Gentamicin in neonatal infection: once versus twice daily dosage. J Med Assoc Thai 2001,84(8),1109-1115","journal-title":"J Med Assoc Thai"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/j.1651-2227.2009.01297.x","volume":"98","author":"Serane T.V.","year":"2009","unstructured":"Serane T.V.; Zengeya S.; Penford G.; Cooke J.; Khanna G.; McGregor-Colman E.; Once daily dose gentamicin in neonates - is our dosing correct? Acta Paediatr 2009,98(7),1100-1105","journal-title":"Acta Paediatr"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1016\/j.clinthera.2011.01.013","volume":"32","author":"Mart\u00ednkov\u00e1 J.","year":"2010","unstructured":"Mart\u00ednkov\u00e1 J.; Pokorn\u00e1 P.; Z\u00e1hora J.; Chl\u00e1dek J.; Vobruba V.; Selke-Krulichov\u00e1 I.; Chl\u00e1dkov\u00e1 J.; Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. Clin Ther 2010,32(14),2400-2414","journal-title":"Clin Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.clinthera.2017.05.343","volume":"39","author":"Sundaram A.","year":"2017","unstructured":"Sundaram A.; Alshaikh B.; Dersch-Mills D.; Dobry J.; Akierman A.R.; Yusuf K.; Extended-interval dosing of gentamicin in premature neonates born at <32 Weeks\u2019 gestation and >7 days of age. Clin Ther 2017,39(6),1233-1241","journal-title":"Clin Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"30021-","DOI":"10.1016\/j.jiac.2020.01.007","volume":"S1341-321X(20),","author":"Sridharan K.","year":"2020,","unstructured":"Sridharan K.; Al Daylami A.; Clinical audit of gentamicin use by Bayesian pharmacokinetic approach in critically ill children. J Infect Chemother, 2020,,S1341-321X(20),,30021--30020.","journal-title":"J Infect Chemother,"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ccc.2010.11.006","volume":"27","author":"Craig W.A.","year":"2011","unstructured":"Craig W.A.; Optimizing aminoglycoside use. Crit Care Clin 2011,27(1),107-121","journal-title":"Crit Care Clin"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02260.x","volume":"59","author":"Lingvall M.","year":"2005","unstructured":"Lingvall M.; Reith D.; Broadbent R.; The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005,59(1),54-61","journal-title":"Br J Clin Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00007691-198901000-00004","volume":"11","author":"Watterberg K.L.","year":"1989","unstructured":"Watterberg K.L.; Kelly H.W.; Angelus P.; Backstrom C.; The need for a loading dose of gentamicin in neonates. Ther Drug Monit 1989,11(1),16-20","journal-title":"Ther Drug Monit"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00007691-199206000-00001","volume":"14","author":"Izquierdo M.","year":"1992","unstructured":"Izquierdo M.; Lanao J.M.; Cervero L.; Jimenez N.V.; Dom\u00ednguez-Gil A.; Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit 1992,14(3),177-183","journal-title":"Ther Drug Monit"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2146\/ajhp160061","volume":"74","author":"Antolik T.L.","year":"2017","unstructured":"Antolik T.L.; Cunningham K.J.; Alabsi S.; Reimer R.A.; Empirical gentamicin dosing based on serum creatinine levels in premature and term neonates. Am J Health Syst Pharm 2017,74(7),466-472","journal-title":"Am J Health Syst Pharm"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijporl.2017.03.025","volume":"97","author":"Garinis A.C.","year":"2017","unstructured":"Garinis A.C.; Liao S.; Cross C.P.; Galati J.; Middaugh J.L.; Mace J.C.; Wood A.M.; McEvoy L.; Moneta L.; Lubianski T.; Coopersmith N.; Vigo N.; Hart C.; Riddle A.; Ettinger O.; Nold C.; Durham H.; MacArthur C.; McEvoy C.; Steyger P.S.; Effect of gentamicin and levels of ambient sound on hearing screening outcomes in the neonatal intensive care unit: A pilot study. Int J Pediatr Otorhinolaryngol 2017,97,42-50","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ijporl.2015.05.036","volume":"79","author":"El-Barbary M.N.","year":"2015","unstructured":"El-Barbary M.N.; Ismail R.I.; Ibrahim A.A.; Gentamicin extended interval regimen and ototoxicity in neonates. Int J Pediatr Otorhinolaryngol 2015,79(8),1294-1298","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpeds.2018.07.101","volume":"203","author":"Puia-Dumitrescu M.","year":"2018","unstructured":"Puia-Dumitrescu M.; Bretzius O.M.; Brown N.; Fitz-Henley J.A.; Ssengonzi R.; Wechsler C.S.; Gray K.D.; Benjamin D.K.; Smith P.B.; Clark R.H.; Gonzalez D.; Hornik C.P.; Gray, K.D.; Benjamin, D.K. Sr.; Smith, P.B.; Clark, R.H.; Gonzalez, D.; Hornik, C.P. Evaluation of gentamicin exposure in the neonatal intensive care unit and hearing function at discharge. J Pediatr 2018,203,131-136","journal-title":"J Pediatr"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1592\/phco.31.7.649","volume":"31","author":"Cooper A.C.","year":"2011","unstructured":"Cooper A.C.; Commers A.R.; Finkelstein M.; Lipnik P.G.; Tollefson L.M.; Wilcox R.A.; Hoff D.S.; Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life. Pharmacotherapy 2011,31(7),649-657","journal-title":"Pharmacotherapy"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/AAC.01314-10","volume":"55","author":"Drusano G.L.","year":"2011","unstructured":"Drusano G.L.; Louie A.; Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011,55(6),2528-2531","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1086\/520991","volume":"45","author":"Drusano G.L.","year":"2007","unstructured":"Drusano G.L.; Ambrose P.G.; Bhavnani S.M.; Bertino J.S.; Nafziger A.N.; Louie A.; Louie A.; Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007,45(6),753-760","journal-title":"Clin Infect Dis"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T14:42:23Z","timestamp":1666536143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181886\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666200512111131","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}